Check out Total Prescribing Information and facts OPDIVO® (nivolumab) is indicated to the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which includes relapsed or progressed right after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or